Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection - Takeaways - MDSpire

Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection

  • By

  • Lorant Leopold

  • Johan Vingerhoets

  • Sofie Deleu

  • Catherine Nalpas

  • Karin Weber

  • Ilse van Dromme

  • David Lowson

  • Bart Michiels

  • Wilbert van Duijnhoven

  • August 22, 2024

  • 0 min

Share

  • 1

    Pimodivir was assessed for efficacy and safety in high-risk adolescents and adults with influenza A in two phase 3 studies.

  • 2

    The combination of pimodivir and standard care showed no clinical benefit over placebo plus standard care in hospitalized patients.

  • 3

    In high-risk outpatients, pimodivir plus standard care demonstrated a shorter median time to resolution of influenza symptoms compared to placebo.

  • 4

    Both studies were randomized, double-blind, and placebo-controlled, involving multiple international sites.

  • 5

    Pimodivir's development addresses the urgent need for effective antiviral treatments for hospitalized influenza patients.

Original Source(s)

Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection

  • by Lorant Leopold, Johan Vingerhoets, Sofie Deleu, Catherine Nalpas, Karin Weber, Ilse van Dromme, David Lowson, Bart Michiels, Wilbert van Duijnhoven

  • August 22, 2024

Related Content

Editorial: Lipid influence on lung immune-structural cell crosstalk: implications for respiratory health

The Evolution of Covid-19: A Retrospective Analysis

Prevalence of Aspergillus spp. in Patients Exhibiting Tuberculosis-like Symptoms in Yaoundé, Cameroon, and Analysis of Antifungal Resistance Patterns